An LNP, or lipid nanoparticle, is a tiny fat-based delivery vehicle used to transport medications, vaccines, or genetic therapies into your cells. Each particle is roughly 100 nanometers across, about a thousand times smaller than a single human hair. If you heard the term during the COVID-19 pandemic, that’s because lipid nanoparticles are the technology that made mRNA vaccines possible. Without them, fragile mRNA molecules would break down in the bloodstream long before reaching your cells.
What LNPs Are Made Of
Every FDA-approved lipid nanoparticle contains four types of fat molecules, each with a specific job:
- Ionizable lipids form the core of the particle and do the heaviest lifting. They change their electrical charge depending on acidity: neutral in the bloodstream, positively charged inside the acidic compartments of your cells. This switch lets them trap the drug cargo during manufacturing and then release it once inside a cell.
- Helper phospholipids give the particle structural stability, much like the outer membrane of a normal cell.
- Cholesterol fills gaps between the other lipids, making the particle sturdier and less likely to leak its contents prematurely.
- PEG-lipids create a “stealth” coating on the surface. This polyethylene glycol layer prevents the particles from clumping together and slows immune detection, so the LNPs circulate in the blood long enough to reach their target.
Think of the whole structure like a microscopic shipping container: a protective outer shell designed to keep its cargo intact until it arrives at the right destination.
How LNPs Get Drugs Into Your Cells
Delivering a drug to the bloodstream is relatively straightforward. The harder problem is getting that drug through a cell’s outer membrane and into the interior where it can actually work. LNPs solve this in a series of steps.
First, cells absorb the nanoparticle through endocytosis, the same process they use to pull in nutrients. The LNP ends up trapped inside a small bubble called an endosome. Normally, anything stuck in an endosome gets shuttled to a recycling or disposal compartment and broken down. This is where ionizable lipids earn their keep.
As the endosome matures, its interior becomes increasingly acidic. That acidity flips the ionizable lipids from neutral to positively charged. The newly charged lipids interact with the negatively charged fats in the endosome’s own membrane, destabilizing it. The endosome essentially ruptures, spilling the drug cargo (mRNA, for example) into the cell’s main interior. From there, the cell’s own machinery reads the mRNA and produces the intended protein, whether that’s a piece of a virus for vaccine training or a therapeutic protein to treat disease.
Approved Medical Uses
The first LNP drug to receive FDA approval was Onpattro in 2018, well before the pandemic. Onpattro treats a rare inherited condition called hereditary transthyretin-mediated amyloidosis, where a misfolded protein gradually damages nerves. The drug uses LNPs to deliver small interfering RNA that silences the gene responsible for producing that harmful protein. It’s given as an intravenous infusion dosed by body weight, typically once every three weeks.
The technology became globally recognized in 2020 and 2021 when both the Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) COVID-19 vaccines used LNPs to deliver mRNA encoding the spike protein of SARS-CoV-2. These were the first mRNA vaccines authorized for widespread use, and their rapid development demonstrated how adaptable LNP platforms can be. Because the manufacturing process is largely standardized, researchers can swap in new mRNA sequences without redesigning the delivery system from scratch.
Why LNPs Replaced Older Delivery Methods
Before lipid nanoparticles, the main option for delivering genetic material into cells was viral vectors: harmless, modified viruses engineered to carry therapeutic genes. Viral vectors are effective, but they come with significant drawbacks. The viral proteins can trigger strong immune reactions, limiting how many doses a patient can safely receive. Manufacturing them at scale is also complex and expensive.
LNPs sidestep these problems. They contain no viral proteins, so the immune response is generally milder and more predictable. Their production relies on established lipid-mixing techniques that scale up relatively easily, which is why billions of mRNA vaccine doses could be manufactured in a short time frame. LNP surfaces can also be modified with targeting molecules to direct them toward specific tissues, a flexibility that viral vectors lack.
Known Side Effects and Limitations
The PEG coating that protects LNPs in the bloodstream is also their most common source of adverse reactions. Some people develop antibodies against PEG, often from prior exposure to PEG-containing products like certain laxatives, cosmetics, or injectable medications. When these anti-PEG antibodies encounter a PEGylated nanoparticle, they can activate the complement system, a branch of the immune response that tags foreign objects for destruction. This leads to faster clearance of the LNPs from the blood, reducing how well the drug works, and can occasionally cause allergic-type reactions including flushing, changes in blood pressure, or shortness of breath.
With repeated doses, this effect can intensify. The antibodies bind to PEG on the nanoparticle surface, triggering immune proteins to coat the particle. Liver immune cells then gobble up the tagged LNPs before they reach their intended target. This “accelerated blood clearance” is one reason researchers are exploring PEG alternatives for next-generation formulations.
Storage Challenges
One practical limitation you may remember from the vaccine rollout is the need for cold storage. The earliest mRNA COVID-19 vaccines required ultra-cold temperatures between negative 90°C and negative 60°C, creating major logistical hurdles for distribution, especially in rural or low-resource settings.
The core issue is chemical stability. At room temperature (25°C), the ionizable lipids inside LNPs begin to break down, and the mRNA they carry starts to fragment. In lab studies, LNPs stored at room temperature maintained their effectiveness for about two weeks before dropping below 50% activity by four weeks. Refrigeration at 4°C is far more forgiving: more than 94% of the key ionizable lipid remained intact after eight weeks, and gene expression held steady over that same period when formulated at the right acidity. Newer formulations have gradually improved shelf life at standard refrigerator temperatures, making distribution simpler with each generation of the technology.
Where LNP Medicine Is Heading
The biggest obstacle to expanding LNP therapies beyond vaccines is organ targeting. After injection, lipid nanoparticles naturally accumulate in the liver. That’s useful for diseases like the one Onpattro treats, but it limits applications for conditions affecting the lungs, brain, spleen, or other organs.
Researchers are working around this by tweaking the lipid recipe. Changing the ratio of the four lipid components or chemically modifying the ionizable lipid alters how proteins in the blood coat the nanoparticle’s surface after injection. This protein coating, called the biomolecular corona, acts like an address label: different corona compositions direct LNPs to different organs. Early results have shown that adjusting the charge or adding specific helper molecules can shift delivery toward the lungs or spleen instead of the liver, opening the door to LNP-based treatments for lung diseases, certain cancers, and immune disorders that require targeting specific cell types outside the liver.